{"id":"anlotinib-hydrochloride-capsules","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hypertension"},{"rate":"20-30","effect":"Proteinuria"},{"rate":"15-25","effect":"Hand-foot skin reaction"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Anorexia"},{"rate":"10-20","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5572229","moleculeType":null,"molecularWeight":"443.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anlotinib hydrochloride inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and growth, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By blocking these pathways, it suppresses new blood vessel formation that tumors depend on for growth and metastasis, thereby inhibiting tumor progression.","oneSentence":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:53.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced non-small cell lung cancer"},{"name":"Soft tissue sarcoma"},{"name":"Medullary thyroid cancer"}]},"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT07438886","phase":"PHASE1","title":"Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2026-03-02","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT05828953","phase":"PHASE2, PHASE3","title":"Anlotinib Capsules in the Treatment for IPF/PF-ILDs","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2021-09-28","conditions":"Interstitial Lung Diseases","enrollment":30},{"nctId":"NCT07385079","phase":"PHASE3","title":"Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":412},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT07165951","phase":"PHASE3","title":"Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-02","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":566},{"nctId":"NCT06438783","phase":"PHASE1","title":"TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-02-15","conditions":"Osteosarcoma, Other Solid Tumors","enrollment":20},{"nctId":"NCT06352008","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Non-Small Cell Lung Cancer","enrollment":64},{"nctId":"NCT06970145","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-04-25","conditions":"Craniopharyngiomas","enrollment":57},{"nctId":"NCT07137884","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":"Rhabdomyosarcoma Recurrent, Maintenance Treatment","enrollment":150},{"nctId":"NCT05975645","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-15","conditions":"Advanced Hepatocellular Carcinoma","enrollment":29},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04574284","phase":"PHASE2","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-09-29","conditions":"Advanced Endometrial Cancer","enrollment":170},{"nctId":"NCT04671303","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-01-01","conditions":"Lung Cancer","enrollment":36},{"nctId":"NCT06429397","phase":"PHASE2","title":"Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Pheochromocytoma","enrollment":22},{"nctId":"NCT06931145","phase":"PHASE4","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06886347","phase":"PHASE1","title":"Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Chen Xiaozhong","startDate":"2023-07-07","conditions":"Metastatic Nasopharyngeal Carcinoma","enrollment":47},{"nctId":"NCT04165330","phase":"PHASE1, PHASE2","title":"Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2019-10-17","conditions":"Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04344158","phase":"PHASE3","title":"A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-11","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":648},{"nctId":"NCT05021328","phase":"PHASE1","title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","status":"COMPLETED","sponsor":"Hubei Cancer Hospital","startDate":"2021-10-01","conditions":"NSCLC","enrollment":13},{"nctId":"NCT06660511","phase":"EARLY_PHASE1","title":"Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-10-15","conditions":"Ovarian Cancer Recurrent","enrollment":5},{"nctId":"NCT06611657","phase":"PHASE2","title":"Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-08-20","conditions":"Whole Brain Radiotherapy","enrollment":40},{"nctId":"NCT04523272","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-25","conditions":"Advanced Renal Cancer","enrollment":528},{"nctId":"NCT06507891","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06469879","phase":"PHASE3","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-09","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":358},{"nctId":"NCT06475599","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":"Endometrial Cancer","enrollment":420},{"nctId":"NCT06341530","phase":"PHASE2","title":"Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-31","conditions":"Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT06222944","phase":"PHASE2","title":"Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2024-02-25","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":90},{"nctId":"NCT06010901","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-01-13","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT05193604","phase":"PHASE1","title":"A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2022-03-24","conditions":"Pancreatic Carcinoma","enrollment":29},{"nctId":"NCT05494060","phase":"PHASE2","title":"XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-16","conditions":"Carcinoma, Gastrointestinal Diseases, Stomach Cancer","enrollment":80},{"nctId":"NCT06102928","phase":"NA","title":"A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation","status":"RECRUITING","sponsor":"Kunming Medical University","startDate":"2023-10-30","conditions":"Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor","enrollment":30},{"nctId":"NCT06062563","phase":"NA","title":"Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-11","conditions":"Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma","enrollment":10},{"nctId":"NCT05996484","phase":"PHASE2","title":"Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-09","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":25},{"nctId":"NCT05994365","phase":"","title":"Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08","conditions":"Thyroid Neoplasms","enrollment":380},{"nctId":"NCT05830500","phase":"PHASE4","title":"Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-19","conditions":"Medullary Thyroid Cancer","enrollment":360},{"nctId":"NCT05942508","phase":"PHASE1","title":"A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2023-05-30","conditions":"Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy","enrollment":20},{"nctId":"NCT05913089","phase":"PHASE2","title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-14","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT05862337","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-10","conditions":"Hepatocellular Carcinoma","enrollment":480},{"nctId":"NCT05736952","phase":"PHASE2","title":"Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-03-01","conditions":"Platinum-resistant Ovarian Cancer","enrollment":""},{"nctId":"NCT05800080","phase":"NA","title":"An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2023-04","conditions":"Gastric Cancer","enrollment":114},{"nctId":"NCT04438902","phase":"PHASE2","title":"Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-12-12","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05252078","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-06-02","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases","enrollment":30},{"nctId":"NCT05559242","phase":"PHASE1","title":"Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-10","conditions":"Liver Dysfunction","enrollment":30},{"nctId":"NCT05549973","phase":"PHASE1","title":"Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT05485350","phase":"PHASE2","title":"Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-09-12","conditions":"Non-Small Cell Lung Cancer","enrollment":32},{"nctId":"NCT04080843","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-11-15","conditions":"Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms","enrollment":30},{"nctId":"NCT05244993","phase":"PHASE2","title":"AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-07","conditions":"Breast Neoplasm Female","enrollment":42},{"nctId":"NCT04772001","phase":"NA","title":"Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2021-03-12","conditions":"Uterine Cervical Neoplasms, Chemoradiotherapy, Angiogenesis","enrollment":53},{"nctId":"NCT05111366","phase":"PHASE2","title":"TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Xianhai Mao","startDate":"2022-01-06","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":37},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT04223583","phase":"PHASE4","title":"Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2019-06-26","conditions":"Soft Tissue Sarcomas","enrollment":70},{"nctId":"NCT04958993","phase":"PHASE1, PHASE2","title":"A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-11-12","conditions":"Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT05121350","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03","conditions":"Soft Tissue Sarcoma","enrollment":256},{"nctId":"NCT05198531","phase":"PHASE1, PHASE2","title":"To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01","conditions":"Recurrent / Metastatic Nasopharyngeal Cancer","enrollment":90},{"nctId":"NCT05089643","phase":"PHASE2","title":"Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-04-11","conditions":"Metastatic Triple-Negative Breast Cancer","enrollment":35},{"nctId":"NCT05145218","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-09-28","conditions":"Recurrent Platinum-resistant Ovarian Cancer","enrollment":405},{"nctId":"NCT05121363","phase":"PHASE2","title":"A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-12","conditions":"Endometrial Carcinoma","enrollment":113},{"nctId":"NCT05124431","phase":"PHASE2","title":"Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT05068206","phase":"PHASE2","title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-10-08","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT04924192","phase":"PHASE2","title":"A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-18","conditions":"Advanced Lung Carcinoma","enrollment":126},{"nctId":"NCT05035914","phase":"PHASE1, PHASE2","title":"Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2021-07-09","conditions":"Advanced Colorectal Cancer","enrollment":94},{"nctId":"NCT05033587","phase":"PHASE2","title":"Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-09","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":28},{"nctId":"NCT04063683","phase":"PHASE2","title":"Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-10-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":47},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT04888546","phase":"PHASE1, PHASE2","title":"TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-30","conditions":"Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi","enrollment":20},{"nctId":"NCT04827004","phase":"PHASE2","title":"A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-04","conditions":"Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT04809142","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-02-04","conditions":"Advanced Biliary Cancer","enrollment":392},{"nctId":"NCT04731909","phase":"NA","title":"Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2018-10-01","conditions":"SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT04620837","phase":"PHASE2","title":"Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-11-01","conditions":"Small Cell Lung Carcinoma","enrollment":25},{"nctId":"NCT04547855","phase":"PHASE2","title":"Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen","status":"UNKNOWN","sponsor":"Yonggao Mou","startDate":"2020-09-11","conditions":"Glioblastoma","enrollment":54},{"nctId":"NCT04507035","phase":"PHASE4","title":"Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-09-01","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT03998085","phase":"NA","title":"Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2019-03-05","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04439890","phase":"PHASE3","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-08-08","conditions":"Advanced Non-squamous Cell Non-small Cell Lung Cancer","enrollment":369},{"nctId":"NCT04405505","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-06-01","conditions":"Triple Negative Breast Cancer","enrollment":332},{"nctId":"NCT04385550","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-20","conditions":"Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma","enrollment":528},{"nctId":"NCT04314297","phase":"PHASE2","title":"Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-04","conditions":"Anlotinib, Durvalumab, Small Cell Lung Cancer","enrollment":33},{"nctId":"NCT04313660","phase":"PHASE2","title":"Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study","status":"UNKNOWN","sponsor":"Xiaorong Dong","startDate":"2020-04","conditions":"NSCLC, Anlotinib, PD-1/L1 Inhibitor","enrollment":33},{"nctId":"NCT04028778","phase":"PHASE3","title":"Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-04-10","conditions":"Lung Cancer, Nonsmall Cell","enrollment":310},{"nctId":"NCT03825705","phase":"PHASE1, PHASE2","title":"A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-04-23","conditions":"Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT03855358","phase":"PHASE1","title":"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-05-09","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT03769805","phase":"NA","title":"Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-06-15","conditions":"Nonsmall Cell Lung Cancer","enrollment":83},{"nctId":"NCT04073550","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT04073537","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":386},{"nctId":"NCT04066543","phase":"PHASE2","title":"TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-30","conditions":"Carcinoma, Hepatocellular","enrollment":40},{"nctId":"NCT04052152","phase":"PHASE2","title":"Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-06-10","conditions":"Advanced Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT03975036","phase":"PHASE2, PHASE3","title":"Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-04-08","conditions":"Advanced Solid Tumor","enrollment":100},{"nctId":"NCT03527888","phase":"PHASE2","title":"Study of Anlotinib in Patients With Primary Malignant Bone Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-01-31","conditions":"Neoplasm of Bone","enrollment":40},{"nctId":"NCT03950518","phase":"PHASE3","title":"Novel Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2019-04-10","conditions":"HCC","enrollment":300},{"nctId":"NCT03940378","phase":"PHASE3","title":"Treatment of Advanced Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2019-02-01","conditions":"ICC","enrollment":152},{"nctId":"NCT03766490","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-03-30","conditions":"Non-Small-Cell Lung","enrollment":66},{"nctId":"NCT03766776","phase":"NA","title":"Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-12-31","conditions":"Cancer of Liver","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fukewei, YBH00802018","AHC"],"phase":"marketed","status":"active","brandName":"Anlotinib hydrochloride capsules","genericName":"Anlotinib hydrochloride capsules","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases. Used for Advanced non-small cell lung cancer, Soft tissue sarcoma, Medullary thyroid cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}